1
|
Carcinogenicity and testicular toxicity of 2-bromopropane in a 26-week inhalation study using the rasH2 mouse model. Sci Rep 2023; 13:1782. [PMID: 36721063 PMCID: PMC9889353 DOI: 10.1038/s41598-023-28825-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 01/25/2023] [Indexed: 02/02/2023] Open
Abstract
2-Bromopropane (2-BP) is a colorless liquid at room temperature and is used in closed systems in factories, mainly as an intermediate for medicines, pesticides, and other chemicals. However, the carcinogenicity of 2-BP is still unknown. The CByB6F1-Tg(HRAS)2Jic (rasH2) transgenic mouse model has been established as an alternative to long-term studies (1.5 years-lifetime) to detect carcinogenicity in as short a time as six months. We performed a 26-week inhalation exposure study of 2-BP using the rasH2 mouse model. Male and female rasH2 mice were exposed to 0, 67, 200, or 600 ppm of 2-BP for 6 h/day, 5 days/week for 26 weeks. All tissues and blood were collected and subjected to biological and histopathological analyses. The results showed a concentration-dependent increase in lung tumor development in male and female rasH2 mice exposed by inhalation to 2-BP, which was significant by Peto's and Poly-3 trend tests. Furthermore, in male rasH2 mice, 2-BP was found to be a testicular toxin. This study is the first to demonstrate that 2-BP is carcinogenic in male and female mice and a testicular toxin in male mice using the rasH2 mouse model.
Collapse
|
2
|
Yamano S, Takeda T, Goto Y, Hirai S, Furukawa Y, Kikuchi Y, Kasai T, Misumi K, Suzuki M, Takanobu K, Senoh H, Saito M, Kondo H, Umeda Y. No evidence for carcinogenicity of titanium dioxide nanoparticles in 26-week inhalation study in rasH2 mouse model. Sci Rep 2022; 12:14969. [PMID: 36056156 PMCID: PMC9440215 DOI: 10.1038/s41598-022-19139-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 08/24/2022] [Indexed: 12/02/2022] Open
Abstract
With the rapid development of alternative methods based on the spirit of animal welfare, the publications of animal studies evaluating endpoints such as cancer have been extremely reduced. We performed a 26-week inhalation exposure studies of titanium dioxide nanoparticles (TiO2 NPs) using CByB6F1-Tg(HRAS)2Jic (rasH2) mice model for detecting carcinogenicity. Male and female rasH2 mice were exposed to 2, 8 or 32 mg/m3 of TiO2 NPs for 6 h/day, 5 days/week for 26 weeks. All tissues and blood were collected and subjected to biological and histopathological analyses. TiO2 NPs exposure induced deposition of particles in lungs in a dose-dependent manner in each exposure group. Exposure to TiO2 NPs, as well as other organs, did not increase the incidence of lung tumors in any group, and pulmonary fibrosis and pre-neoplastic lesions were not observed in all groups. Finally, the cell proliferative activity of alveolar epithelial type 2 cells was examined, and it was not increased by exposure to TiO2 NPs. This is the first report showing the lack of pulmonary fibrogenicity and carcinogenicity (no evidence of carcinogenic activity) of TiO2 NPs in 26-week inhalation study in rasH2 mice exposed up to 32 mg/m3, which is considered to be a high concentration.
Collapse
Affiliation(s)
- Shotaro Yamano
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan.
| | - Tomoki Takeda
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan.
| | - Yuko Goto
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Shigeyuki Hirai
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Yusuke Furukawa
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Yoshinori Kikuchi
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Tatsuya Kasai
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Kyohei Misumi
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Masaaki Suzuki
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Kenji Takanobu
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Hideki Senoh
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Misae Saito
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Hitomi Kondo
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| | - Yumi Umeda
- Japan Bioassay Research Center, Japan Organization of Occupational Health and Safety, 2445 Hirasawa, Hadano, Kanagawa, 257-0015, Japan
| |
Collapse
|
3
|
Tsutsumi H, Inoue R, Yasuda M, Takahashi R, Suzuki M, Urano K. rasH2 mouse: reproducibility and stability of carcinogenicity due to a standardized production and monitoring system. J Toxicol Pathol 2022; 35:19-24. [PMID: 35221492 PMCID: PMC8828604 DOI: 10.1293/tox.2021-0068] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Accepted: 11/04/2021] [Indexed: 11/19/2022] Open
Affiliation(s)
- Hideki Tsutsumi
- Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
| | - Ryo Inoue
- Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
| | - Masahiko Yasuda
- Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
| | - Riichi Takahashi
- Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
| | - Masami Suzuki
- Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
| | - Koji Urano
- Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan
| |
Collapse
|
4
|
Okamura M, Moto M, Kashida Y, Machida N, Mitsumori K. Carcinogenic Susceptibility to N-bis(2-hydroxypropyl)nitrosamine (DHPN) in rasH2 Mice. Toxicol Pathol 2021; 32:474-81. [PMID: 15223773 DOI: 10.1080/01926230490483315] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
To evaluate the susceptibility of rasH2 mice to N-bis(2-hydroxypropyl)nitrosamine (DHPN), a potent carcinogen targeting the lung, liver, thyroid, and kidney, male, 6-week old, rasH2 mice and wild-type Iittermates (non-Tg mice) were given DHPN in drinking water at 0, 20 or 200 ppm, and 0 or 200 ppm, respectively, for 26 weeks. The experiment using rasH2 mice given 200 ppm DHPN and non-Tg mice given 200 and 0 ppm DHPN was completed at 20 weeks, since mortality in these groups was remarkably increased due to hemangiosarcomas of the liver. Histologically, tumors developed in the lung and liver in both rasH2 and non-Tg mice treated with DHPN. In addition, proliferative lesions were observed in the forestomach, urethra, and excretory duct of salivary glands in rasH2 mice given 200 ppm DHPN. RT-PCR analysis showed no marked difference in expression of mRNAs for the transgene and the endogenous mouse ras gene between the whole lung tissue containing a neoplasm and normal lung tissue. Our results suggest that rasH2 mice are highly susceptible to DHPN, the target organs including the forestomach, salivary gland and urethra, which have not been found to develop tumors in previous long-term carcinogenicity studies of DHPN in rats and mice.
Collapse
Affiliation(s)
- Miwa Okamura
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Tokyo 183-8509, Japan.
| | | | | | | | | |
Collapse
|
5
|
Paranjpe MG, Rudmann D, Sargeant A, Morse M, Yonpiam R, Bonnette K, Albretsen J, Papagiannis C. Proposal to Eliminate Urethane-Treated Positive Control Dose Groups in 26-Week Tg.rasH2 Carcinogenicity Studies. Int J Toxicol 2021; 40:207-210. [PMID: 33813924 DOI: 10.1177/10915818211003308] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Short-term (26 weeks) Tg.rasH2 mouse carcinogenicity studies have been conducted as an alternative model to the conventional 2-year mouse carcinogenicity studies, using urethane as a positive control material. In these studies, urethane was used at a dose of 1,000 mg/kg/dose, administered intraperitoneally on days 1, 3, and 5. Urethane consistently produces lung adenomas and carcinomas and hemangiosarcomas of the spleen, proving validity of the assay. We conducted 3 pilot studies at 3 different sites of Charles River Laboratories using a lower dose of urethane (500 mg/kg/dose), administered on days 1, 3, and 5, followed by a 12-week observation period. Our results demonstrate that a lower dose can be used successfully with fewer number of animals per sex to prove the validity of the assay. However, based on our cumulative experience with this model, we propose to eliminate positive control dose groups in future Tg.rasH2 carcinogenicity studies.
Collapse
Affiliation(s)
| | | | | | - Mark Morse
- 537465Charles River Laboratories, Mattawan, MI, USA
| | | | | | | | | |
Collapse
|
6
|
Mepham TB, Combes RD, Balls M, Barbieri O, Blokhuis HJ, Costa P, Crilly RE, de Cock Buning T, Delpire VC, O'Hare MJ, Houdebine LM, van Kreijl CF, van der Meer M, Reinhardt CA, Wolf E, van Zeller AM. The Use of Transgenic Animals in the European Union. Altern Lab Anim 2020. [DOI: 10.1177/026119299802600108] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- T. Ben Mepham
- ECVAM, JRC Environment Institute, 21020 Ispra (VA), Italy
| | - Robert D. Combes
- Dipartimento di Oncologia Clinica e Sperimentale, Università di Genova, IST/CBA, Largo R. Benzi 10, 16132 Genoa, Italy
| | - Michael Balls
- Institute for Animal Science and Health (ID-DL), Department of Behaviour, Stress Physiology and Management, Edelhertweg 15, 8200 AB Lelystad, The Netherlands
| | - Ottavia Barbieri
- Instituto di Biologia Molecolare, Via Pontina KM 30.600, 00040 Pomezia, Rome, Italy
| | - Harry J. Blokhuis
- Department for the Study of Animal Experiments, University of Leiden, 2301 CB Leiden, The Netherlands
| | - Patrizia Costa
- Breast Cancer Laboratory, LICR/UCL, 67–73 Riding House Street, London W1P 7LD, UK
| | | | - Tjard de Cock Buning
- Laboratoire de Biologie Cellulaire et Moleculaire, Institut National de la Recherche Agronomique, Domaine de Vilvert, 78352 Jouy-en-Josas, France
| | - Véronique C. Delpire
- Institute for Animal Science and Health (ID-DL), Department of Behaviour, Stress Physiology and Management, Edelhertweg 15, 8200 AB Lelystad, The Netherlands
| | | | - Louis-Marie Houdebine
- Laboratoire de Biologie Cellulaire et Moleculaire, Institut National de la Recherche Agronomique, Domaine de Vilvert, 78352 Jouy-en-Josas, France
| | | | - Miriam van der Meer
- Department of Laboratory Animal Science, Utrecht University, 3508 TD Utrecht, The Netherlands
| | | | - Eckhard Wolf
- Lehrstuhl für Molekulare Tierzucht, Feodor-Lynen-Strasse 25, 81377 Munich, Germany
| | - Anne-Marie van Zeller
- Dipartimento di Oncologia Clinica e Sperimentale, Università di Genova, IST/CBA, Largo R. Benzi 10, 16132 Genoa, Italy
| |
Collapse
|
7
|
Webster JD, Santagostino SF, Foreman O. Applications and considerations for the use of genetically engineered mouse models in drug development. Cell Tissue Res 2019; 380:325-340. [DOI: 10.1007/s00441-019-03101-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Accepted: 08/22/2019] [Indexed: 02/07/2023]
|
8
|
Mepham TB, Combes RD, Balls M, Barbieri O, Blokhuis HJ, Costa P, Crilly RE, de Cock Buning T, Delpire VC, O'Hare MJ, Houdebine LM, van Kreijl CF, van der Meer M, Reinhardt CA, Wolf E, van Zeller AM. The Use of Transgenic Animals in the European Union. Altern Lab Anim 2019. [DOI: 10.1177/026119299902701s02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- T. Ben Mepham
- Centre for Applied Bioethics, University of Nottingham, Sutton Bonington Campus, Loughborough, LE12 5RD, UK
| | - Robert D. Combes
- FRAME, Russell & Burch House, 96–98 North Sherwood Street, Nottingham, NG1 4EE, UK
| | - Michael Balls
- ECVAM, JRC Environment Institute, 21020 Ispra (VA), Italy
| | - Ottavia Barbieri
- Dipartimento di Oncologia Clinica e Sperimentale, Università di Genova, IST/CBA, Largo R. Benzi 10, 16132 Genoa, Italy
| | - Harry J. Blokhuis
- Institute for Animal Science and Health (ID-DL), Department of Behaviour, Stress Physiology and Management, Edelhertweg 15, 8200 AB Lelystad, The Netherlands
| | - Patrizia Costa
- Instituto di Biologia Molecolare, Via Pontina KM 30.600, 00040 Pomezia, Rome, Italy
| | - Robert E. Crilly
- Centre for Applied Bioethics, University of Nottingham, Sutton Bonington Campus, Loughborough, LE12 5RD, UK
| | - Tjard de Cock Buning
- Department for the Study of Animal Experiments, University of Leiden, 2301 CB Leiden, The Netherlands
| | | | - Michael J. O'Hare
- Breast Cancer Laboratory, LICR/UCL, 67–73 Riding House Street, London W1P 7LD, UK
| | - Louis-Marie Houdebine
- Laboratoire de Biologie Cellulaire et Moleculaire, Institut National de la Recherche Agronomique, Domaine de Vilvert, 78352 Jouy-en-Josas, France
| | | | - Miriam van der Meer
- Department of Laboratory Animal Science, Utrecht University, 3508 TD Utrecht, The Netherlands
| | | | - Eckhard Wolf
- Lehrstuhl für Molekulare Tierzucht, Feodor-Lynen-Strasse 25, 81377 Munich, Germany
| | | |
Collapse
|
9
|
Hoivik DJ, Allen JS, Wall HG, Nold JB, Miller RT, Santostefano MJ. Studies Evaluating the Utility of N-Methyl-N-Nitrosourea as a Positive Control in Carcinogenicity Studies in the p53+/– Mouse. Int J Toxicol 2016; 24:349-56. [PMID: 16257854 DOI: 10.1080/10915810500210385] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Studies conducted under the auspices of International Life Sciences Institute (ILSI) have suggested that an alternative mouse carcinogenicity study may be substituted for the traditional 2-year mouse bioassay typically conducted to support the development of drug candidates. The purpose of this study was to characterize the carcinogenic potential of N-methyl- N-nitrosourea (MNU), a DNA alkylating agent, in p53+ /– knockout mice to determine its suitability as a positive control agent in an alternative carcinogenicity model. p53+ /– knockout mice were administered a single oral dose of 90 mg/kg and maintained for up to 13 weeks prior to evaluation of neoplasms. Treatment was generally well tolerated; however, 4 of 30 mice died between the days of 75 and 92 due to neoplasms. MNU-related macroscopic observations included enlargement of the thymus, spleen, mandibular and mesenteric lymph nodes; and pale liver, heart, kidney, and bone marrow, which correlated with the diagnosis of lymphoma of the hematopoietic system, noted in the thymus of all affected animals and in the spleen, liver, lungs, and kidneys of some animals. Other treatment-related single neoplasms included a squamous-cell carcinoma in the nonglandular stomach and leiomyosarcoma in the glandular stomach. Non-neoplastic proliferative lesions included acanthosis and hyperkeratosis in the nonglandular stomach, focal papillary hyperplasia of the nonglandular stomach, glandular hyperplasia of the stomach, and adenomatous hyperplasia of the duodenum or ileum. The increased incidence of neoplastic and proliferative changes in MNU-treated mice suggests MNU could serve as a positive control in alternative carcinogenicity studies conducted in p53+ /– knockout mice.
Collapse
Affiliation(s)
- Debie J Hoivik
- GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA
| | | | | | | | | | | |
Collapse
|
10
|
Lina BAR, Woutersen RA, Bruijntjes JP, van Benthem J, van den Berg JAH, Monbaliu J, Thoolen BJJM, Beems RB, van Kreijl CF. Evaluation of the Xpa-Deficient Transgenic Mouse Model for Short-Term Carcinogenicity Testing: 9-Month Studies with Haloperidol, Reserpine, Phenacetin, and D-Mannitol. Toxicol Pathol 2016; 32:192-201. [PMID: 15200157 DOI: 10.1080/01926230490274344] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
As part of the international evaluation program coordinated by ILSI/HESI, the potential of DNA repair deficient Xpa- /- mice and the double knockout Xpa- /- .p53+ /- mice for short term carcinogenicity assays was evaluated. For comparison also wild-type C57BL/6 mice (WT) were included in these studies. Four test compounds were administered to groups of 15 male and 15 female Xpa- /- mice, Xpa- /- .p53+ /- mice and WT mice for 39 weeks. The model compounds investigated were haloperidol, reserpine (nongenotoxic rodent carcinogens, putative human noncarcinogens), phenacetin (genotoxic rodent carcinogen, suspected human carcinogen), and D-mannitol (noncarcinogen in rodents and humans). The test compounds were administered as admixture to rodent diet at levels up to 25 mg/kg diet for haloperidol, 7.5 mg/kg diet for reserpine, 0.75% for phenacetin, and 10% for D-mannitol. These levels included the maximum tolerable dose (MTD). Survival was not affected with any of the test compounds. Haloperidol, reserpine and D-mannitol were negative in the carcinogenicity assay with Xpa- /- and Xpa- /- .p53+ /- mice, showing low and comparable tumor incidences in controls and high-dose animals. The results obtained with phenacetin may be designated equivocal in Xpa- /- .p53+ /- mice, based on the occurrence of a single rare tumor in the target organ (kidney) accompanied by a low incidence of hyperplastic renal lesions and a high incidence of karyomegaly. These results are in agreement with the currently known carcinogenic potential of the 4 test compounds in humans.
Collapse
Affiliation(s)
- Ben A R Lina
- TNO Nutrition and Food Research, Zeist, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Matsuoka Y, Fukamachi K, Hamaguchi T, Toriyama-Baba H, Kawaguchi H, Kusunoki M, Yoshida H, Tsuda H. Rapid Emergence of Mammary Preneoplastic and Malignant Lesions in Human c-Ha-ras Proto-Oncogene Transgenic Rats: Possible Application for Screening of Chemopreventive Agents. Toxicol Pathol 2016; 31:632-7. [PMID: 14585731 DOI: 10.1080/01926230390241882] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
For comparison of mammary gland whole mounts with examination of 2 histologic sections of mammary gland, 56 Hras128 rats were intravenously injected with 50 mg/kg body weight of N-methyl- N-nitrosourea at 50 days of age and then sacrificed at days 5, 10, 15, 20, 25, and 56. Comparison of detection sensitivity between the whole mounts and histologic sections revealed no lesions apparent in whole mounts on day 10, although intraductal proliferation was clearly detected in histologic sections in 44% of treated rats. Proliferative lesions were first detected in whole mounts at a 44% incidence on day 15, while intraductal proliferations and atypical hyperplasias were apparent in the sections at 89% and 44% incidences, respectively. On day 20, atypical hyperplasias and small adenocarcinomas in histologic sections were found in almost all animals. In conclusion, examination of 2 histologic sections from mammary tissues was found to be practical for detection of small malignant lesions as early as 15 days after MNU injection, and suppressive effects of soy isoflavones were clearly evident within 20 days after carcinogen exposure. These results suggest that this model has practical utility for short-term screening of chemopreventive agents for mammary carcinogenesis.
Collapse
Affiliation(s)
- Yoichiro Matsuoka
- Experimental Pathology and Chemotherapy Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Ozaki M, Ozaki K, Watanabe T, Uwagawa S, Okuno Y, Shirai T. Susceptibilities of p53 Knockout and rasH2 Transgenic Mice to Urethane-Induced Lung Carcinogenesis are Inherited from their Original Strains. Toxicol Pathol 2016; 33:267-71. [PMID: 15902970 DOI: 10.1080/01926230590908231] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
In the present study, susceptibility of CB6F1 mice carrying the human prototype c-Ha- ras gene (rasH2 mice) and p53 gene knockout mice ( p53 (+/−) mice) to urethane-induced lung carcinogenesis was compared under the same experimental conditions. Both strains were administered 500 ppm urethane in their drinking water for 3 weeks. At week 26, lung adenocarcinomas and adenomas were observed in 53% and 100% of rasH2 mice, respectively, and lung adenomas were observed in 67% of rasH2 littermate (non-Tg) mice. However, lung tumors were not observed in either p53 (+/−) or p53 (+/+) mice. Peliosis hepatis and hepatic hemangiomas were observed in 27% and 67% of p53 (+/−) mice, but only in 6.7% and 6.7% of the rasH2 animals, respectively. Under the same experimental conditions, BALB/c mice, the strain of origin of the rasH2 mice, developed lung adenomas at an incidence of 93%, whereas none of the C57BL/6 original strain for p53 (+/−) mice developed lung tumors. Peliosis hepatis was observed in 40% of the C57BL/6 mice, but not in BALB/c mice; hepatic and splenic hemangiomas were not observed in these animals. These results indicate that organ susceptibility of rasH2 and p53 (+/−) mice is inherited from their strains of origin, the rasH2 and BALB/c lines being much more sensitive to the induction of pulmonary carcinogenesis.
Collapse
Affiliation(s)
- Masakazu Ozaki
- Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences, Mizuho-ku, Nagoya 467-8601, Japan.
| | | | | | | | | | | |
Collapse
|
13
|
Ohnishi T, Fukamachi K, Ohshima Y, Jiegou X, Ueda S, Iigo M, Takasuka N, Naito A, Fujita KI, Matsuoka Y, Izumi K, Tsuda H. Possible Application of Human c-Ha-ras Proto-Oncogene Transgenic Rats in a Medium-Term Bioassay Model for Carcinogens. Toxicol Pathol 2016; 35:436-43. [PMID: 17474063 DOI: 10.1080/01926230701302541] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
With the aim of developing a medium-term assay for screening of environmental carcinogens, we exposed mammary carcinogen sensitive human c-Ha-ras proto-oncogene transgenic (Hras128) rats to various carcinogens, including compounds that do not normally induce mammary tumors. Seven-week-old Hras128 rats and wild-type littermates received administrations of 3-methylcholanthrene (3-MC), benzo[a]pyrene (B[a]P), anthracene, pyrene, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), dimethylarsinic acid (DMA), diethylnitrosamine (DEN) or azoxymethane (AOM) and were sacrificed at week 12 (females) (at week 10 for the 3-MC group) or week 20 (males). Female Hras128 rats receiving NNK, DEN, or DMA showed a significant increase in mammary tumor incidence and/or multiplicity compared to the respective values with olive oil or deionized distilled water (DDW) vehicles. In male Hras128 rats, a significant increase in mammary tumors was also observed in groups administered 3-MC, B[a]P, anthracene, IQ, and NNK. Mutations of transgenes were observed in codons 12 and/or 61 in the induced tumors by PCR-RFLP except in the DEN group in female and in the MeIQx group in male Hras128 rats. Thus various carcinogens, not necessarily limited to those normally targeting the breast, were found to induce mammary carcinomas in Hras128 rats, especially in females, pointing to potential use for medium-term screening.
Collapse
Affiliation(s)
- Takamasa Ohnishi
- Department of Molecular and Environmental Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Okamura M, Moto M, Muguruma M, Ito T, Jin M, Kashida Y, Mitsumori K. A 26-Week Carcinogenicity Study of 2-Amino-3-Methylimidazo[4,5-f]Quinoline in rasH2 Mice. Toxicol Pathol 2016; 34:199-205. [PMID: 16537296 DOI: 10.1080/01926230600640058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
To evaluate the carcinogenic susceptibility of rasH2 mice to 2-amino-3-methylimidazo[4,5- f ]quinoline (IQ), 7-week-old rasH2 mice and their wild-type littermates (non-Tg mice) of both the sexes were fed a diet containing 0 or 300 ppm IQ for 26 weeks. Microscopical examinations revealed that the proliferative lesions of the forestomach, including squamous cell hyperplasias, papillomas, and carcinomas, were frequently encountered in male and female rasH2 mice fed with IQ. In non-Tg mice, no significant differences in the incidence of forestomach lesions were observed between the 0 ppm and 300 ppm groups. Histopathological changes such as periportal hepatocellular hypertrophy and oval cell proliferation in the liver were more apparent in female rasH2 and non-Tg mice than in males, and the incidence of hepatocellular altered foci significantly increased in female rasH2 mice in the 300 ppm group as compared to that in the 0 ppm group. These results suggest that the carcinogenic potential of IQ can be detected in rasH2 mice by a 26-week, short-term carcinogenicity test.
Collapse
Affiliation(s)
- Miwa Okamura
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu City, Tokyo, Japan.
| | | | | | | | | | | | | |
Collapse
|
15
|
Tsuji S, Kuwahara Y, Takagi H, Sugiura M, Nakanishi Y, Wakamatsu M, Tsuritani K, Sato Y. Gene expression analysis in the lung of the rasH2 transgenic mouse at week 4 prior to induction of malignant tumor formation by urethane and N-methylolacrylamide. J Toxicol Sci 2015; 40:685-700. [DOI: 10.2131/jts.40.685] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Affiliation(s)
- Satoshi Tsuji
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd
| | | | - Hironori Takagi
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd
| | - Masayuki Sugiura
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd
| | - Yutaka Nakanishi
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd
| | - Masaki Wakamatsu
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd
| | | | - Yasushi Sato
- Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd
| |
Collapse
|
16
|
Kawabe M, Urano K, Suguro M, Numano T, Taguchi F, Tsutsumi H, Furukawa F. Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate in an Ultra-Short-Term Skin Carcinogenesis Bioassay Using rasH2 Mice. Vet Pathol 2013; 50:903-8. [DOI: 10.1177/0300985813486811] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Assessment of the skin tumor–promoting potential of 12- O-tetradecanoylphorbol-13-acetate (TPA) after initiation with 7,12-dimethylbenz[ a]anthracene (DMBA) was conducted using rasH2 transgenic (Tg) mice and their nontransgenic (non-Tg) littermates. Mice were treated with DMBA (50 μg/100 μL acetone) on clipped back skin at the commencement of the study, and 1 week thereafter, TPA was applied at 8 μg/200 μL or 4 μg/200 μL acetone, once or twice weekly, for 7 weeks. Skin nodules were observed in the rasH2 Tg mice from week 4, and the incidence reached 100% at weeks 5 and 6. The number of skin nodules (multiplicity) in the 8-μg twice-weekly, 8-μg once-weekly, 4-μg twice-weekly, and 4-μg once-weekly groups was 62.4, 46.2, 62.6, and 36.9, respectively. The non-Tg mice also developed skin nodules, but the sensitivity to induction in the rasH2 Tg mice was higher. No nodules were observed in the acetone groups, but single nodules were apparent in the no-treatment rasH2 Tg and non-Tg groups. In conclusion, skin promotion effects could be detected within only 8 weeks in the rasH2 mice, and the concentration of 4 μg TPA once weekly was sufficient as a positive control. This short-term skin carcinogenesis bioassay using rasH2 mice could represent a useful tool for the assessment of drug and chemical safety with cutaneous treatment.
Collapse
Affiliation(s)
- M. Kawabe
- DIMS Institute of Medical Science, Inc., Azai-cho, Ichinomiya, Japan
| | - K. Urano
- Central Institute for Experimental Animals, Kawasaki-ku, Kawasaki, Japan
| | - M. Suguro
- DIMS Institute of Medical Science, Inc., Azai-cho, Ichinomiya, Japan
| | - T. Numano
- DIMS Institute of Medical Science, Inc., Azai-cho, Ichinomiya, Japan
| | - F. Taguchi
- CLEA Japan, Inc., Meguro-ku, Tokyo, Japan
| | - H. Tsutsumi
- Central Institute for Experimental Animals, Kawasaki-ku, Kawasaki, Japan
| | - F. Furukawa
- DIMS Institute of Medical Science, Inc., Azai-cho, Ichinomiya, Japan
| |
Collapse
|
17
|
|
18
|
Shah SA, Paranjpe MG, Atkins PI, Zahalka EA. Reduction in the Number of Animals and the Evaluation Period for the Positive Control Group in Tg.rasH2 Short-Term Carcinogenicity Studies. Int J Toxicol 2012; 31:423-9. [DOI: 10.1177/1091581812458957] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The lack of a clear guidance on the adequate number of animals used for positive controls in the short-term (26-weeks) transgenic mouse carcinogenicity studies has resulted in the use of high number of animals. In our earlier Tg.rasH2 studies, 25 mice/sex were used in the urethane-positive control dose groups that were sacrificed by 18 weeks. Based on a robust response, several of our protocols for Tg.rasH2 studies with 15 mice/sex and terminal sacrifice at 17 ± 1 weeks were submitted and accepted by the Carcinogenicity Assessment Committee of the US Food and Drug Administration since we demonstrated close to 100% response for the development of lung and splenic tumors (target organs) in 500 mice/sex. These 500 mice/sex included 17 groups of 25 mice/sex and 5 groups of 15 mice/sex. The objective of this investigation was to determine whether the number of animals can be further reduced along with the shortened duration of exposure to urethane. Accordingly, 10 Tg.rasH2 mice/sex/group were administered a total of 3 intraperitoneal (IP) injections of urethane (1000 mg/kg per day) on study days 1, 3, and 5, and the presence of tumors in the lungs and spleen was evaluated after 8, 10, 12, 14, or 16 weeks. Our results demonstrate that 100% of the mice at 8 weeks had developed lung tumors, whereas close to 100% of the mice at 14 weeks had developed splenic tumors. Based on the development of lung tumors alone in 100% of the mice, we recommend that 10 mice/sex are sufficient and that these mice can also be sacrificed as early as 10 ± 1 weeks following the administration of urethane.
Collapse
Affiliation(s)
- Sudhir A. Shah
- Division of Toxicology, BioReliance Corporation, Rockville, MD 20850, USA
| | | | - Philip I. Atkins
- Division of Toxicology, BioReliance Corporation, Rockville, MD 20850, USA
| | - Eias A. Zahalka
- Division of Toxicology, BioReliance Corporation, Rockville, MD 20850, USA
| |
Collapse
|
19
|
Hueper K, Elalfy M, Laenger F, Halter R, Rodt T, Galanski M, Borlak J. PET/CT imaging of c-Myc transgenic mice identifies the genotoxic N-nitroso-diethylamine as carcinogen in a short-term cancer bioassay. PLoS One 2012; 7:e30432. [PMID: 22319569 PMCID: PMC3271108 DOI: 10.1371/journal.pone.0030432] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2011] [Accepted: 12/20/2011] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND More than 100,000 chemicals are in use but have not been tested for their safety. To overcome limitations in the cancer bioassay several alternative testing strategies are explored. The inability to monitor non-invasively onset and progression of disease limits, however, the value of current testing strategies. Here, we report the application of in vivo imaging to a c-Myc transgenic mouse model of liver cancer for the development of a short-term cancer bioassay. METHODOLOGY/PRINCIPAL FINDINGS μCT and ¹⁸F-FDG μPET were used to detect and quantify tumor lesions after treatment with the genotoxic carcinogen NDEA, the tumor promoting agent BHT or the hepatotoxin paracetamol. Tumor growth was investigated between the ages of 4 to 8.5 months and contrast-enhanced μCT imaging detected liver lesions as well as metastatic spread with high sensitivity and accuracy as confirmed by histopathology. Significant differences in the onset of tumor growth, tumor load and glucose metabolism were observed when the NDEA treatment group was compared with any of the other treatment groups. NDEA treatment of c-Myc transgenic mice significantly accelerated tumor growth and caused metastatic spread of HCC in to lung but this treatment also induced primary lung cancer growth. In contrast, BHT and paracetamol did not promote hepatocarcinogenesis. CONCLUSIONS/SIGNIFICANCE The present study evidences the accuracy of in vivo imaging in defining tumor growth, tumor load, lesion number and metastatic spread. Consequently, the application of in vivo imaging techniques to transgenic animal models may possibly enable short-term cancer bioassays to significantly improve hazard identification and follow-up examinations of different organs by non-invasive methods.
Collapse
Affiliation(s)
- Katja Hueper
- Institute for Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany
| | - Mahmoud Elalfy
- Department of Molecular Medicine and Medical Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany
| | - Florian Laenger
- Institute for Pathology, Hannover Medical School, Hannover, Germany
| | - Roman Halter
- Department of Molecular Medicine and Medical Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany
| | - Thomas Rodt
- Institute for Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany
| | - Michael Galanski
- Institute for Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany
| | - Juergen Borlak
- Department of Molecular Medicine and Medical Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany
- Centre for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany
- * E-mail:
| |
Collapse
|
20
|
Urano K, Tamaoki N, Nomura T. Establishing a Laboratory Animal Model From a Transgenic Animal. Vet Pathol 2011; 49:16-23. [DOI: 10.1177/0300985811430318] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Transgenic animal models have been used in small numbers in gene function studies in vivo for a period of time, but more recently, the use of a single transgenic animal model has been approved as a second species, 6-month alternative (to the routine 2-year, 2-animal model) used in short-term carcinogenicity studies for generating regulatory application data of new drugs. This article addresses many of the issues associated with the creation and use of one of these transgenic models, the rasH2 mouse, for regulatory science. The discussion includes strategies for mass producing mice with the same stable phenotype, including constructing the transgene, choosing a founder mouse, and controlling both the transgene and background genes; strategies for developing the model for regulatory science, including measurements of carcinogen susceptibility, stability of a large-scale production system, and monitoring for uniform carcinogenicity responses; and finally, efficient use of the transgenic animal model on study. Approximately 20% of mouse carcinogenicity studies for new drug applications in the United States currently use transgenic models, typically the rasH2 mouse. The rasH2 mouse could contribute to animal welfare by reducing the numbers of animals used as well as reducing the cost of carcinogenicity studies. A better understanding of the advantages and disadvantages of the transgenic rasH2 mouse will result in greater and more efficient use of this animal model in the future.
Collapse
Affiliation(s)
- K. Urano
- Central Institute for Experimental Animals (CIEA), Kawasaki, Japan
| | - N. Tamaoki
- Central Institute for Experimental Animals (CIEA), Kawasaki, Japan
| | - T. Nomura
- Central Institute for Experimental Animals (CIEA), Kawasaki, Japan
| |
Collapse
|
21
|
Kadonosono T, Kuchimaru T, Yamada S, Takahashi Y, Murakami A, Tani T, Watanabe H, Tanaka T, Hirota K, Inoue M, Tsukamoto T, Toyoda T, Urano K, Machida K, Eto T, Ogura T, Tsutsumi H, Ito M, Hiraoka M, Kondoh G, Kizaka-Kondoh S. Detection of the onset of ischemia and carcinogenesis by hypoxia-inducible transcription factor-based in vivo bioluminescence imaging. PLoS One 2011; 6:e26640. [PMID: 22102864 PMCID: PMC3213102 DOI: 10.1371/journal.pone.0026640] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2011] [Accepted: 09/29/2011] [Indexed: 12/20/2022] Open
Abstract
An animal model for the early detection of common fatal diseases such as ischemic diseases and cancer is desirable for the development of new drugs and treatment strategies. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that regulates oxygen homeostasis and plays key roles in a number of diseases, including cancer. Here, we established transgenic (Tg) mice that carry HRE/ODD-luciferase (HOL) gene, which generates bioluminescence in an HIF-1-dependent manner and was successfully used in this study to monitor HIF-1 activity in ischemic tissues. To monitor carcinogenesis in vivo, we mated HOL mice with rasH2 Tg mice, which are highly sensitive to carcinogens and are used for short-term carcinogenicity assessments. After rasH2-HOL Tg mice were treated with N-methyl-N-nitrosourea, bioluminescence was detected noninvasively as early as 9 weeks in tissues that contained papillomas and malignant lesions. These results suggest that the Tg mouse lines we established hold significant potential for monitoring the early onset of both ischemia and carcinogenesis and that these lines will be useful for screening chemicals for carcinogenic potential.
Collapse
MESH Headings
- Alkylating Agents/toxicity
- Animals
- Blotting, Southern
- Carcinogenicity Tests/methods
- Female
- Genes, ras
- Humans
- Hypoxia-Inducible Factor 1/metabolism
- Image Processing, Computer-Assisted
- Ischemia/chemically induced
- Ischemia/diagnosis
- Ischemia/metabolism
- Luminescent Measurements
- Luminescent Proteins/metabolism
- Male
- Methylnitrosourea/toxicity
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Transgenic
- Neoplasms, Experimental/chemically induced
- Neoplasms, Experimental/diagnosis
- Neoplasms, Experimental/metabolism
- Papilloma/chemically induced
- Papilloma/diagnosis
- Papilloma/metabolism
- RNA, Messenger/genetics
- Real-Time Polymerase Chain Reaction
Collapse
Affiliation(s)
- Tetsuya Kadonosono
- Department of Biomolecular Engineering, Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology, Nagatsuta-cho, Midori-ku, Yokohama, Japan
| | - Takahiro Kuchimaru
- Department of Biomolecular Engineering, Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology, Nagatsuta-cho, Midori-ku, Yokohama, Japan
| | - Shuichi Yamada
- Animal Research Laboratory, Bioscience Research and Education Center, Akita University, Akita, Japan
| | - Yumi Takahashi
- Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto, Japan
| | - Atsushi Murakami
- Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto, Japan
| | - Taeko Tani
- Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto, Japan
| | - Hitomi Watanabe
- Laboratory of Animal Experiments for Regeneration, Institute for Frontier Medical Sciences, Kyoto, Japan
| | - Tomoharu Tanaka
- Department of Anesthesia, Kyoto University, Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan
| | - Kiichi Hirota
- Department of Anesthesia, Kyoto University, Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan
| | - Masahiro Inoue
- Department of Biochemistry, Osaka Medical Center for Cancer and Cardiovascular Disease, Nakamichi, Higashinari-ku, Osaka, Japan
| | - Tetsuya Tsukamoto
- Division of Oncological Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Takeshi Toyoda
- Division of Oncological Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Koji Urano
- Central Institute for Experimental Animals, Nogawa, Miyamae, Kawasaki, Japan
| | - Kazuhiko Machida
- Central Institute for Experimental Animals, Nogawa, Miyamae, Kawasaki, Japan
| | - Tomoo Eto
- Central Institute for Experimental Animals, Nogawa, Miyamae, Kawasaki, Japan
| | - Tomoyuki Ogura
- Central Institute for Experimental Animals, Nogawa, Miyamae, Kawasaki, Japan
| | - Hideki Tsutsumi
- Central Institute for Experimental Animals, Nogawa, Miyamae, Kawasaki, Japan
| | - Mamoru Ito
- Central Institute for Experimental Animals, Nogawa, Miyamae, Kawasaki, Japan
| | - Masahiro Hiraoka
- Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto, Japan
| | - Gen Kondoh
- Laboratory of Animal Experiments for Regeneration, Institute for Frontier Medical Sciences, Kyoto, Japan
| | - Shinae Kizaka-Kondoh
- Department of Biomolecular Engineering, Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology, Nagatsuta-cho, Midori-ku, Yokohama, Japan
- * E-mail:
| |
Collapse
|
22
|
Park HJ, Oh JH, Park SM, Cho JW, Yum YN, Park SN, Yoon DY, Yoon S. Identification of biomarkers of chemically induced hepatocarcinogenesis in rasH2 mice by toxicogenomic analysis. Arch Toxicol 2011; 85:1627-40. [PMID: 21607683 DOI: 10.1007/s00204-011-0715-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2010] [Accepted: 05/09/2011] [Indexed: 01/24/2023]
Abstract
Toxicogenomic approaches have been applied to chemical-induced heptocarcinogenesis rodent models for the identification of biomarkers of early-stage hepatocarcinogenesis and to help clarify the underlying carcinogenic mechanisms in the liver. In this study, we used toxiciogenomic methods to identify candidate biomarker genes associated with hepatocarcinogenesis in rasH2 mice. Blood chemical, histopathologic, and gene expression analyses of the livers of rasH2 mice were performed 7 and 91 days after the administration of the genotoxic hepatocarcinogens 2-acetylaminofluorene (AAF) and diethylnitrosoamine (DEN), the genotoxic carcinogen melphalan (Mel), and the nongenotoxic noncarcinogen 1-naphthylisothiocynate (ANIT). Histopathologic lesions and a rise in accompanying serum marker levels were found in the DEN-treated rasH2 mice, whereas no neoplastic lesions were observed in the rasH2 mice. However, biological functional analysis using Ingenuity Pathways Analysis (IPA) software revealed that genes with comparable molecular and cellular functions were similarly deregulated in the AAF- and DEN-treated rasH2 mice. We selected 68 significantly deregulated genes that represented a hepatocarcinogen-specific signature; these genes were commonly deregulated in both the AAF- and DEN-treated rasH2 mice on days 7 and 91. Hierarchical clustering analysis indicated that the expression patterns of the selected genes in the hepatocarcinogen (AAF and DEN) groups were distinctive from the patterns in the control, Mel, and ANIT groups. Biomarker filter analysis using IPA software suggested that 28 of the 68 signature genes represent promising candidate biomarkers of cancer. Quantitative real-time PCR analysis confirmed that the deregulated genes, which exhibited sustained up- and down-regulation up to day 91, are likely involved in early-stage hepatocarcinogenesis. In summary, the common and significant gene expression changes induced by AAF and DEN may reflect early molecular events associated with hepatocarcinogenesis, and these "signature" genes may be useful as biomarkers of hepatocarcinogenesis in mice.
Collapse
Affiliation(s)
- Han-Jin Park
- Division of Research and Development, Korea Institute of Toxicology, 19 Shinsung-ro, Yuseong-gu, Daejeon 305-343, Korea
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Bugelski PJ, Volk A, Walker MR, Krayer JH, Martin P, Descotes J. Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human Neoplasia. Int J Toxicol 2010; 29:435-66. [DOI: 10.1177/1091581810374654] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Many immunosuppressive drugs are associated with an increased risk of B-cell lymphoma, squamous cell carcinoma, and Kaposi sarcoma. Thirteen immunosuppressive drugs have been tested in 2-year carcinogenicity studies (abatacept; azathioprine; busulfan; cyclophosphamide; cyclosporine; dexamethasone; everolimus; leflunomide; methotrexate; mycophenolate mofetil; prednisone; sirolimus; and tacrolimus) and in additional models including neonatal and genetically modified mice; chemical, viral, ultraviolet, and ionizing radiation co-carcinogenesis, and in models with transplanted tumor cells. The purpose of this review is to outline the mechanisms by which immunosuppressive drugs can influence neoplasia, to summarize the available preclinical data on the 13 drugs, and to critically review the performance of the models. A combination of primary tumor and metastasis assays conducted with transplanted cells may provide the highest value for hazard identification and can be applied on a case-by-case basis. However, for both small molecules and therapeutic proteins, determining the relative risk to patients from preclinical data remains problematic. Classifying immunosuppressive drugs based on their mechanism of action and hazard identification from preclinical studies and a prospective pharmacovigilance program to monitor carcinogenic risk may be a feasible way to manage patient safety during the clinical development program and postmarketing.
Collapse
Affiliation(s)
| | - Amy Volk
- Biologics Toxicology, Centocor R&D, Radnor, PA, USA
| | | | | | | | - Jacques Descotes
- Centre Antipoison–Centre de Pharmacovigilance, Hôpital Edouard Herriot, Lyon, France
| |
Collapse
|
24
|
NARUSHIMA S, SAKATA T, HIOKI K, ITOH T, NOMURA T, ITOH K. Inhibitory Effect of Yogurt on Aberrant Crypt Foci Formation in the Rat Colon and Colorectal Tumorigenesis in RasH2 Mice. Exp Anim 2010; 59:487-94. [DOI: 10.1538/expanim.59.487] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Affiliation(s)
- Seiko NARUSHIMA
- Laboratory of Veterinary Public Health, The University of Tokyo
| | | | | | | | | | - Kikuji ITOH
- Laboratory of Veterinary Public Health, The University of Tokyo
| |
Collapse
|
25
|
Storer RD, Sistare FD, Vijayaraj Reddy M, Degeorge JJ. An Industry Perspective on the Utility of Short-Term Carcinogenicity Testing in Transgenic Mice in Pharmaceutical Development. Toxicol Pathol 2009; 38:51-61. [PMID: 19893055 DOI: 10.1177/0192623309351718] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
International guidelines allow for use of a short-term cancer bioassay (twenty-six weeks) in transgenic mice as a substitute for one of the two required long-term rodent bioassays in the preclinical safety evaluation of pharmaceuticals. The two models that have gained the widest acceptance by sponsors and regulatory authorities are the CB6F1-RasH2 mouse hemizygous for a human H-ras transgene and the B6.129N5-Trp53 mouse heterozygous for a p53 null allele. The p53+/- model is of particular value for compounds with residual concern that genotoxic activity may contribute to tumorigenesis. The rasH2 model is an appropriate alternative without regard to evidence of genotoxic potential. Since results from a short-term bioassay can be obtained relatively early in drug development, there is the potential for more timely assessment of cancer risk for individuals in long-term clinical trials. Use of these models in preclinical safety evaluation also significantly reduces animal use, time, and manpower. Preliminary findings indicate that prediction of two-year rat bioassay outcomes based on data from chronic rat toxicity studies, together with early assessment of carcinogenic potential in short-term transgenic models, may have the potential to increase the timeliness and efficiency of strategies for the identification of human carcinogenic hazards.
Collapse
Affiliation(s)
- Richard D. Storer
- Dept. of Safety Assessment, Merck Research Laboratories,
West Point, Pennsylvania, USA,
| | - Frank D. Sistare
- Dept. of Safety Assessment, Merck Research Laboratories,
West Point, Pennsylvania, USA
| | - M. Vijayaraj Reddy
- Dept. of Safety Assessment, Merck Research Laboratories,
West Point, Pennsylvania, USA
| | - Joseph J. Degeorge
- Dept. of Safety Assessment, Merck Research Laboratories,
West Point, Pennsylvania, USA
| |
Collapse
|
26
|
Palazzi X, Kergozien-Framery S. Use of rasH2 transgenic mice for carcinogenesis testing of medical implants. ACTA ACUST UNITED AC 2008; 61:433-41. [PMID: 19062264 DOI: 10.1016/j.etp.2008.10.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2008] [Revised: 10/13/2008] [Accepted: 10/21/2008] [Indexed: 10/21/2022]
Abstract
Several transgenic mice models are accepted by regulatory agencies to determine the carcinogenic potential and predict the human response to exposure of chemicals, as an alternative to the conventional 2-year rodent bioassay. The rasH2 transgenic mouse model has been proposed to evaluate the carcinogenic potential of medical devices, but few data are currently available regarding study design--namely appropriate positive and negative controls to be used--as well as historical pathology data. BIOMATECH-NAMSA recently conducted a 26-week carcinogenicity study following subcutaneous implantation in the transgenic rasH2 mouse model. This paper describes the study design and the main results obtained in the positive and negative control groups. The survival rate statistical (Kaplan-Meier) analysis showed that the survival rate was significantly affected by the occurrence of tumors in the positive control group when compared to the negative control group, in both genders. Thymic malignant lymphomas and squamous cell papillomas were reported to occur at a higher incidence in rasH2 mice exposed to a known chemical carcinogen, for terminally sacrificed animals as well as for unscheduled and terminally sacrificed animals considered together. Background and age-related lesions were few. Taken together, these data confirmed the reliability and usefulness of the rasH2 transgenic model in the assessment of carcinogenic properties of medical devices. A major beneficial property of this animal model consisted in the ability to demonstrate chemical carcinogenesis response without the solid-state tumorigenesis response seen in traditional 2-year rodent bioassays.
Collapse
Affiliation(s)
- Xavier Palazzi
- BIOMATECH-NAMSA, 115 rue Pasteur, Zi de L'Islon, Chasse sur Rhone, France.
| | | |
Collapse
|
27
|
Kawai M, Jin M, Nishimura J, Dewa Y, Saegusa Y, Matsumoto S, Taniai E, Shibutani M, Mitsumori K. Hepatocarcinogenic Susceptibility of Fenofibrate and Its Possible Mechanism of Carcinogenicity in a Two-Stage Hepatocarcinogenesis Model of rasH2 Mice. Toxicol Pathol 2008; 36:950-7. [DOI: 10.1177/0192623308327118] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Fenofibrate (FF) has previously been shown to induce hepatocellular neoplasia in a conventional mouse bioassay (NDA 1993), but there has been no report to examine the carcinogenic susceptibility of rasH2 mice to this chemical. In the present study, male rasH2 mice were subjected to a two-thirds partial hepatectomy (PH), followed by an N-diethylnitrosamine (DEN) initiation twenty-four hours after PH, and given a diet containing 0, 1200, or 2400 ppm FF for seven weeks. The incidences of preneoplastic foci were significantly increased in mice from the FF-treated groups. Immunohistochemistry revealed that significant increases in proliferating cell nuclear antigen (PCNA)-positive cells and cytokeratin 8/18 positive foci were observed in FF-treated groups. In addition, the transgene and several downstream molecules such as c- myc, c- jun, activating transcription factor 3 (ATF3), and cyclin D1 were overexpressed in these groups. These results suggest that the hepatocarcinogenic activity of rasH2 mice to FF can be detected in this hepatocarcinogenesis model and that up-regulation of genes for the ras/MAPK pathway and cell cycle was probably involved in the hepatocarcinogenic mechanism of rasH2 mice.
Collapse
Affiliation(s)
- Masaomi Kawai
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
- Pathogenetic Veterinary Science, United Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu 501-1193, Japan
| | - Meilan Jin
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
- Department of Applied Biological Science, United Graduate School of Agricultural Sciences, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
| | - Jihei Nishimura
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
- Pathogenetic Veterinary Science, United Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu 501-1193, Japan
| | - Yasuaki Dewa
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
- Pathogenetic Veterinary Science, United Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu 501-1193, Japan
| | - Yukie Saegusa
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
- Pathogenetic Veterinary Science, United Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu 501-1193, Japan
| | - Sayaka Matsumoto
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
- Pathogenetic Veterinary Science, United Graduate School of Veterinary Sciences, Gifu University, Gifu, Gifu 501-1193, Japan
| | - Eriko Taniai
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
| | - Makoto Shibutani
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
| | - Kunitoshi Mitsumori
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8509, Japan
| |
Collapse
|
28
|
Bhogal N. Genetically altered mice, man and medicine. J Appl Biomed 2008. [DOI: 10.32725/jab.2008.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
29
|
Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model. Arch Toxicol 2008; 83:173-81. [PMID: 18597072 DOI: 10.1007/s00204-008-0335-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2008] [Accepted: 06/18/2008] [Indexed: 01/20/2023]
Abstract
Six-week-old rasH2 mice were injected intraperitoneally with N-diethylnitrosamine (DEN) after partial hepatectomy and administrated 0 or 6,000 ppm troglitazone (TRG) for 10 weeks. Relative liver weight of females increased significantly in the DEN + TRG group compared to the DEN-alone group. The numbers of gamma-glutamyltranspeptidase- and proliferating cell nuclear antigen (PCNA)-positive cells tended to increase in both the sexes in the DEN + TRG group; however, these changes were not significantly different from those in the DEN-alone group. Levels of gene expressions for vascular endothelial growth factor (VEGF) and VEGFB (related to angiogenesis), tropomyosin 1 (Tpm1) and transforming growth factor-beta (related to ras/MAPK cascade activation), and PCNA (related to cell proliferation) in females were significantly higher in the DEN + TRG than in the untreated control group but not in the DEN-alone group. Only Tpm1 gene had significantly higher expression in the DEN + TRG group than in the DEN-alone group. These results suggest that rasH2 mice are not susceptible to TRG in a two-stage hepatocarcinogenesis model.
Collapse
|
30
|
Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. Arch Toxicol 2008; 82:771-7. [PMID: 18465119 DOI: 10.1007/s00204-008-0293-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2007] [Accepted: 03/03/2008] [Indexed: 10/22/2022]
Abstract
To examine the tumor-promoting effect of troglitazone (TRG), a novel thiazolidinedione insulin-sensitizing agent, on splenic hemangiosarcomas in rasH2 mice, histopathological and molecular analyses were performed in the spleen of female rasH2 mice fed a diet containing 6,000 or 0 ppm TRG for 16 weeks after 1,000 or 0 mg/kg urethane (UR) initiation. Histopathologically, splenic hemangiosarcomas were observed in the UR-alone and UR + TRG groups, but there was no significant difference in the incidence of splenic hemangiosarcomas between the UR-alone and UR+TRG groups. There were increasing tendencies in the number of positive cells for anti-PCNA antibody and gene expression in the UR + TRG group, but such a change was not statistically significant as compared to that in the UR-alone group. The gene expressions of VEGF, VEGFR1, VEGFC, VEGFR2 and Tie2 related to angiogenesis; c-fos related to MAPK cascade activation; and cyclin D1 related to cell cycle in the UR-alone and UR + TRG groups were significantly higher than those in the untreated control group. However, only the Tie2 gene in the UR + TRG group was significantly increased as compared to that in the UR-alone group. These results suggest that the vascular tumor-promoting activity of TRG in rasH2 mice is extremely low in the present experimental condition and a part of the gene related to angiogenesis probably contributes to the promotion of splenic hemangiosarcomas in rasH2 mice given TRG.
Collapse
|
31
|
Katoku K, Oshikata T, Kumabe S, Kuwasaki E, Mitsuishi M, Nakahara Y, Hamamura M. Epithelial Proliferative Lesions in the Nasal Cavities of c-Ha-ras Transgenic Mice. J Toxicol Pathol 2008. [DOI: 10.1293/tox.21.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Koshirou Katoku
- Kumamoto laboratory, Mitsubishi Chemical Safety Institute Ltd
| | | | - Shino Kumabe
- Kumamoto laboratory, Mitsubishi Chemical Safety Institute Ltd
| | - Emiko Kuwasaki
- Kumamoto laboratory, Mitsubishi Chemical Safety Institute Ltd
| | - Mikio Mitsuishi
- Kumamoto laboratory, Mitsubishi Chemical Safety Institute Ltd
| | - Yutaka Nakahara
- Kumamoto laboratory, Mitsubishi Chemical Safety Institute Ltd
| | - Masao Hamamura
- Kumamoto laboratory, Mitsubishi Chemical Safety Institute Ltd
| |
Collapse
|
32
|
Jin M, Takahashi M, Moto M, Muguruma M, Ito K, Watanabe K, Kenmochi Y, Kono T, Hasumi K, Mitsumori K. Carcinogenic susceptibility of rasH2 mice to troglitazone. Arch Toxicol 2007; 81:883-94. [PMID: 17569031 DOI: 10.1007/s00204-007-0218-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2007] [Accepted: 05/22/2007] [Indexed: 11/29/2022]
Abstract
To evaluate the carcinogenicity of troglitazone in rasH2 mice, 7-week-old male and female rasH2 mice were fed a diet containing 0, 3,000 or 6,000 ppm troglitazone for 26 weeks. An increased tendency in the incidence of vascular tumors was observed in females of the 6,000 ppm group. The preliminary analysis using a high-density oligonucleotide microarray on a splenic hemangiosarcoma of a high dose female that could be obtained as a fresh sample showed that several genes related to the ras/MAPK pathway activation, angiogenesis, cell cycle and cell multiplication were up-regulated. In addition, most of the genes up-regulated were confirmed by the reverse transcriptase-polymerase chain reaction (RT-PCR). These results may suggest that the carcinogenic susceptibility of rasH2 mice to troglitazone is relatively low and up-regulations of the ras/MAPK pathway and angiogenesis-related genes are probably involved in the production of splenic hemangiosarcomas in rasH2 mice given troglitazone.
Collapse
Affiliation(s)
- Meilan Jin
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo, 183-8509, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
The completely assembled human genome has made it possible for modern medicine to step into an era rich in genetic information and high-throughput genomic analysis. These novel and readily available genetic resources and analytical tools may be the key to unravel the molecular basis of hepatocellular carcinoma (HCC). Moreover, since an efficient treatment for this disease is lacking, further understanding of the genetic background of HCC will be crucial in order to develop new therapies aimed at selected targets. We report on the current status and recent developments in HCC genetics. Special emphasis is given to the genetics and regulation of major signalling pathways involved in HCC such as p53, Wnt-signalling, TGFβ, Ras, and Rb pathways. Furthermore, we describe the influence of chromosomal aberrations as well as of DNA methylation. Finally, we report on the rapidly developing field of genomic expression profiling in HCC, mainly by microarray analysis.
Collapse
Affiliation(s)
- Andreas Teufel
- Department of Medicine, Johannes Gutenberg University, Building 301, Langenbeckstr. 1, 55101 Mainz, Germany.
| | | | | | | | | | | |
Collapse
|
34
|
Okamura M, Unami A, Moto M, Muguruma M, Ito T, Jin M, Oishi Y, Kashida Y, Mitsumori K. The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rasH2 mice. Cancer Lett 2007; 245:321-30. [PMID: 16530936 DOI: 10.1016/j.canlet.2006.01.025] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2005] [Revised: 11/28/2005] [Accepted: 01/16/2006] [Indexed: 11/25/2022]
Abstract
Microarray and RT-PCR analyses were performed for the transgene and Ras-related genes in forestomach squamous cell carcinomas (SCCs) induced by 7,12-dimethylbenz[a]anthracene (DMBA) in rasH2 mice; these results were compared with our previous molecular data of N-ethyl-N-nitrosourea-induced forestomach SCCs and urethane-induced lung adenomas in rasH2 mice. Overexpression of the transgene was detected in the DMBA-induced SCCs, suggesting that the transgene plays an important role in enhanced carcinogenesis in rasH2 mice. In addition, the mouse endogenous ras genes were up-regulated in the DMBA-induced SCCs, and are probably involved in the tumorigenesis of forestomach SCCs. Genes such as osteopontin, Cks1b, Tpm1, Reck, gelsolin, and amphiregulin that were commonly altered in these three different carcinogen-induced tumors may contribute to the development of tumors in rasH2 mice.
Collapse
Affiliation(s)
- Miwa Okamura
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu City, Tokyo 183-8509, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
The impetus to develop useful models of human disease and toxicity has resulted in a number of large-scale mouse mutagenesis programmes. This, in turn, has stimulated considerable concern regarding the scientific validity and welfare of genetically altered mice, and the large numbers of mice that are required by such programmes. In this paper, the scientific advantages and limitations of genetically altered mice as models of several human diseases are discussed. We conclude that, while the use of some such mouse models has contributed considerably to an understanding of human disease and toxicity, other genetically altered mouse models have limited scientific relevance, and fewer have positively contributed to the development of novel human medicines. Suggestions for improving this unsatisfactory situation are made.
Collapse
Affiliation(s)
- Nirmala Bhogal
- FRAME, 96-98 North Sherwood Street, Nottingham, NG1 4EE, UK.
| | | |
Collapse
|
36
|
Muto S, Katsuki M, Horie S. Rapid induction of skin tumors in human but not mouse c-Ha-ras proto-oncogene transgenic mice by chemical carcinogenesis. Cancer Sci 2006; 97:842-7. [PMID: 16805855 PMCID: PMC11158362 DOI: 10.1111/j.1349-7006.2006.00256.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
The rasH2 transgenic mice carry human c-Ha-ras proto-oncogene, and are highly susceptible to chemical carcinogenesis. Previous studies showed that the mutation of c-Ha-ras induced by DMBA in the tumors of rasH2 were detected only in transgenes. To examine if the difference between the codons of the c-Ha-ras gene in human and mouse contributed to the tissue-specific sensitivity to DMBA, we generated a line of transgenic mice, mras, carrying mouse c-Ha-ras genome with its own promoter. Western blot analysis showed that the protein expression of H-RAS in the skin was increased in both rasH2 and mras compared with wild-type. Chemical skin carcinogenesis was induced by DMBA and TPA. In rasH2 mice, the latency of tumor formation was shorter than wild-type littermates. Both the number and the volume of skin tumors were increased in rasH2 than those of wild-type. However, in mras mice, enhancement of tumor formation was not observed as compared with wild-type. The mean number of tumors and the latency of tumor development was almost the same between mras and wild-type littermates. Mutational analysis showed only A to T transversion in human c-Ha-ras transgenes at codon 61 but not in murine endogenous c-Ha-ras gene in the tumors of rasH2. In the tumors of wild-type littermates and mras, A to T transversion in murine c-Ha-ras at codon 61 were detected. These results indicate that the differences in the codon of the c-Ha-ras gene between mouse and human might contribute to the tissue-specific sensitivity of DMBA.
Collapse
MESH Headings
- 9,10-Dimethyl-1,2-benzanthracene/toxicity
- Animals
- Base Sequence
- Blotting, Western
- Carcinogens/toxicity
- DNA Mutational Analysis
- Genes, ras/genetics
- Humans
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Neoplasms, Squamous Cell/chemically induced
- Neoplasms, Squamous Cell/genetics
- Neoplasms, Squamous Cell/pathology
- Oncogene Protein p21(ras)/biosynthesis
- Point Mutation
- Polymerase Chain Reaction
- Promoter Regions, Genetic
- Proto-Oncogene Mas
- Pyridines/toxicity
- Skin Neoplasms/chemically induced
- Skin Neoplasms/genetics
- Skin Neoplasms/pathology
- Species Specificity
Collapse
Affiliation(s)
- Satoru Muto
- Department of Urology, Teikyo University, 2-11-1, Kaga, Tokyo 173-8605, Japan
| | | | | |
Collapse
|
37
|
Umemura T, Kodama Y, Nishikawa A, Hioki K, Nomura T, Kanki K, Kuroiwa Y, Ishii Y, Kurokawa Y, Hirose M. Nine-week detection of six genotoxic lung carcinogens using the rasH2/BHT mouse model. Cancer Lett 2006; 231:314-8. [PMID: 16399233 DOI: 10.1016/j.canlet.2005.02.024] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2004] [Revised: 02/02/2005] [Accepted: 02/10/2005] [Indexed: 11/23/2022]
Abstract
A 9-week in vivo rasH2/butylhydroxytoluene (BHT) model for the detection of genotoxic lung carcinogens was validated, using six potent positive test compounds, dimethylnitrosamine (DMN; 15 mg/kg, i.p.), diethylnitrosamine (DEN; 100 mg/kg, i.p.), ethylnitrosourea (ENU; 120 mg/kg, i.p.), 3-methylcholanthrene (MC; 100 mg/kg, i.p.), 7,12-dimethylbenz(a)anthracene (DMBA; 5 mg/kg, i.g.) and benzo(a)pyrene (B(a)P; 80 mg/kg, i.p.), each given to rasH2 mice of both genders by single administration for initiation followed by promoter BHT treatment. Statistically significant increase in the incidence and multiplicity of lung tumors was observed in rasH2 mice treated with BHT following exposure to all of the carcinogens tested. The data overall suggest the rasH2/BHT model to be a powerful screening tool for genotoxic lung carcinogens.
Collapse
Affiliation(s)
- Takashi Umemura
- Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Matsuo S, Okamura M, Takizawa T, Imai T, Mitsumori K, Hirose M. Lack of Modifying Effects of Combined Treatment of t-butylhydroquinone and Sodium Nitrite on Forestomach Carcinogenesis in rasH2 Mice Initiated with N-ethyl-N-nitrosourea. J Toxicol Pathol 2005. [DOI: 10.1293/tox.18.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Saori Matsuo
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology
| | - Miwa Okamura
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology
| | | | - Toshio Imai
- Division of Pathology, National Institute of Health Sciences
| | - Kunitoshi Mitsumori
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology
| | - Masao Hirose
- Division of Pathology, National Institute of Health Sciences
| |
Collapse
|
39
|
Yamazaki M, Moto M, Takizawa T, Kashida Y, Imai T, Mitsumori K, Hirose M. Tumorigenic Susceptibility of Catechol on the Gastric Mucosa in rasH2 Mice. J Toxicol Pathol 2005. [DOI: 10.1293/tox.18.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Masaki Yamazaki
- Laboratory of Veterinary of Pathology, Tokyo University of Agriculture and Technology
| | - Mitsuyoshi Moto
- Laboratory of Veterinary of Pathology, Tokyo University of Agriculture and Technology
| | | | - Yoko Kashida
- Laboratory of Veterinary of Pathology, Tokyo University of Agriculture and Technology
| | - Toshio Imai
- Division of Pathology, National Institute of Health
| | - Kunitoshi Mitsumori
- Laboratory of Veterinary of Pathology, Tokyo University of Agriculture and Technology
| | - Masao Hirose
- Division of Pathology, National Institute of Health
| |
Collapse
|
40
|
Suemizu H, Kito-Maruyama C, Sotomaru Y, Ogura T, Hioki K, Ohnishi Y, Tamaoki N. PCR method for genotyping and zygosity-testing of RasH2 transgenic mice. Exp Anim 2004; 53:463-6. [PMID: 15516796 DOI: 10.1538/expanim.53.463] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
In short-term carcinogenicity testing using CB6F1-TgrasH2 mice, sibling nonTgrasH2 mice are used as a negative control. However, selection of TgrasH2 and nonTgrasH2 mice has been performed by PCR with only transgene specific primers by the conventional method. Therefore, the conventional method involves the risk of false negative results due to reaction failure, and contamination with TgrasH2 mice in the control mice group. Based on the nucleotide sequence information around the pre-integration site, we developed a genotyping method for distinguishing not only TgrasH2 mice (hemizygous for the Tg allele) but also nonTgrasH2 (homozygous for the nonTg allele) in a positive manner.
Collapse
|
41
|
Okamura M, Sumida K, Muto T, Kashida Y, Machida N, Watanabe T, Mitsumori K. Analysis of gene expression profiles of forestomach tumors in rasH2 mice initiated with N-ethyl-N-nitrosourea. Arch Toxicol 2004; 78:688-96. [PMID: 15249993 DOI: 10.1007/s00204-004-0589-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2004] [Accepted: 06/08/2004] [Indexed: 10/26/2022]
Abstract
To clarify the mechanisms underlying enhancement of carcinogenesis in transgenic mice carrying a human prototype c-Ha- ras gene (rasH2 mouse), animals received a single intraperitoneal injection of 120 mg/kg N-ethyl-N-nitrosourea (ENU) and at 20 weeks thereafter expression profiles in three induced forestomach squamous cell carcinomas were assessed using high-density oligonucleotide microarrays. In addition, the reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to assess mRNA expression of human c-Ha- ras gene and some molecules involved in the Ras-regulated mitogen-activated protein kinase (MAPK) pathway. Compared with normal forestomach tissue from control mice, 416 and 368 genes, respectively, were found to be commonly up- and down-regulated by 2-fold or more in the three tumors. Many genes involved in tumor invasion and metastasis such as transforming growth factor beta1 and matrix metalloproteinases were up-regulated, reflecting tumor progression. RT-PCR analysis confirmed up-regulation of transgene, mouse endogenous Ha- ras, N- ras, raf, Mekk2, c- fos, junB, c- myc and cyclin D1. These results suggest that activation of the Ras-MAPK cascade following up-regulation of both human and mouse endogenous ras genes is involved in the enhanced tumorigenesis of ENU-induced forestomach squamous cell carcinomas in rasH2 mice.
Collapse
Affiliation(s)
- Miwa Okamura
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, 183-8509, Tokyo, Japan.
| | | | | | | | | | | | | |
Collapse
|
42
|
Park CB, Fukamachi K, Takasuka N, Han BS, Kim CK, Hamaguchi T, Fujita KI, Ueda S, Tsuda H. Rapid induction of skin and mammary tumors in human c-Ha-ras proto-oncogene transgenic rats by treatment with 7,12-dimethylbenz[a]anthracene followed by 12-O-tetradecanoylphorbol 13-acetate. Cancer Sci 2004; 95:205-10. [PMID: 15016318 PMCID: PMC11158931 DOI: 10.1111/j.1349-7006.2004.tb02204.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
We have established a transgenic rat line carrying 3 copies of the human c-Ha-ras proto-oncogene with its own promoter region (Jcl/SD-TgN(HrasGen)128Ncc) (Hras128 rat), expression being detectable in almost all organs. We have already demonstrated that the rat is highly sensitive to mammary, esophagus and bladder carcinogenesis. In the present study, male and female transgenic and wild-type littermates were topically treated with 2.5 mg of 7,12-dimethylbenz[a]anthracene (DMBA) dissolved in 1.0 ml of acetone on the back skin at 50 days after birth. Starting 1 week thereafter, they were again topically treated with 100 nmol of 12-O-tetradecanoylphorbol 13-acetate (TPA) dissolved in 0.5 ml of acetone 3 times weekly for the following 31 weeks. In males treated with DMBA and/or TPA, skin tumors, including both squamous cell papillomas (SCP) and carcinomas (SCC), were preferentially induced at the DMBA-TPA painting sites: DMBA-TPA, 15/15 (100%); DMBA, 6/8 (75%); TPA, 1/6 (16.7%). They were also, unexpectedly, induced on remote scrotal skin: DMBA-TPA, 13/15 (86.7%); DMBA, 5/8 (62.5%); TPA, 0/6 (0%). Lesions were thus more frequent in the DMBA-TPA group than with DMBA or TPA alone. In females, adenomas and adenocarcinomas of the mammary glands were preferentially induced: DMBA-TPA, 12/14 (85.7%); DMBA, 6/8 (75%); TPA, 3/6 (50%), with only a few small skin papillomas at painting sites. Incidences and numbers of the mammary and skin tumors were much greater in Hras128 rats than in their wild-type counterparts. PCR-RFLP analysis of the transgene indicated that the percentage of the cell populations harboring a mutation in codons 12 and/or 61 ranged from 2% to 60% in individual tumors; skin tumors showed more mutations in codon 61 in the DMBA-treated groups. In contrast, no mutations were detected in the endogenous rat c-Ha-ras gene. These results indicate that the Hras128 rat is highly susceptible to DMBA-TPA skin and mammary carcinogenesis, thus providing a unique painting model for skin as well as mammary gland carcinogenesis, that would be suitable for investigating the role of transgene mutations.
Collapse
Affiliation(s)
- Cheol Beom Park
- Experimental Pathology and Chemotherapy Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Imaoka M, Satoh H, Furuhama K. Lack of Carcinogenicity of Reserpine in Transgenic Mice Carrying a Human Prototype c-Ha-ras Gene (RasH2 Mice). J Toxicol Pathol 2004. [DOI: 10.1293/tox.17.95] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Masako Imaoka
- Drug Safety Research Laboratory, Daiichi Pharmaceutical Co., Ltd
| | - Hiroshi Satoh
- Drug Safety Research Laboratory, Daiichi Pharmaceutical Co., Ltd
| | | |
Collapse
|
44
|
Toyosawa K, Tanaka K, Imai T, Yasuhara K, Koujitani T, Hirose M, Mitsumori K. Mutation and overexpression of the transgene in ethylnitrosourea-induced tumors in mice carrying a human prototype c-Ha-ras gene. Toxicol Pathol 2003; 31:491-5. [PMID: 14692617 DOI: 10.1080/01926230390224683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
To investigate mechanisms underlying accelerated carcinogenesis in mice carrying a human prototype c-Ha-ras gene (rasH2 mouse), mutations and the expression profile of the transgene were evaluated in 14 tumors induced by a single injection of ethylnitrosourea (ENU), with or without additional beta-estradiol 3-benzoate (EB) treatment. Although no codon 12 mutations were detected, changes in codon 61 were evident in all lung adenocarcinomas, skin squamous cell carcinomas and forestomach squamous cell carcinomas examined. The mRNA levels of the transgene in these lesions were also elevated 1.71- to 4.77-fold, 3.04- to 5.18-fold, and 3.00- to 5.67-fold, respectively, in comparison with those in the normal livers of rasH2 mice. The results obtained in this study suggest that mutations in codon 61 and amplification of the transgene play key roles in the carcinogenesis induced by ENU in rasH2 mice.
Collapse
Affiliation(s)
- Kaoru Toyosawa
- Safety Research Laboratories, Dainippon Pharmaceutical Co, Ltd, Suita, Osaka 564-0053, Japan.
| | | | | | | | | | | | | |
Collapse
|
45
|
Hirabayashi Y, Yoshida K, Aizawa SI, Kodama Y, Kanno J, Kurokawa Y, Yoshimura I, Inoue T. Evaluation of nonthreshold leukemogenic response to methyl nitrosourea in p53-deficient C3H/He mice. Toxicol Appl Pharmacol 2003; 190:251-61. [PMID: 12902196 DOI: 10.1016/s0041-008x(03)00185-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The classic controversy of whether genotoxic chemicals induce cancers with or without a certain low-dose limit, i.e., the threshold, is revisited because of a number of current publications available addressing the plausibility of "practical" thresholds even for genotoxic carcinogens, the mechanism of which may be hypothesized to be due, in part, to a repair system composed of ordinarily available various defense mechanisms under the steady-state DNA damage. The question of whether an absolute nonthreshold or a relative nonthreshold, i.e., a "practical" threshold specifically in the low-dose level, is present may not be answered even with the use of a prohibitively large number of wild-type mice. Could the excessive incidence of tumorigenesis in p53-deficient mice contribute to our understanding of the threshold vs nonthreshold issue in genotoxic carcinogenesis? This is considered because an exaggeration of tumorigenesis in p53-deficient mice is hypothesized to reduce or eliminate the range of threshold due to the p53-deficiency-mediated reduction of DNA repair and apoptosis. The present study of chemical leukemogenesis in p53-deficient mice by transplantation assay was designed to answer this question. Briefly, 218 C3H/He mice were lethally irradiated and repopulated with bone marrow cells from wild-type, heterozygous p53-deficient, and homozygous p53-deficient C3H/He mice. This was followed by treatment with a single and graded dose of methyl nitrosourea at 6.6, 14.8, 33.3, 50.0, and 75.0 mg/kg body wt, with the vehicle-treated control groups treated with zero dose for each genotype. Whereas mice repopulated with p53-deficient bone marrow cells showed a marked reduction of the threshold for leukemogenicity, mice repopulated with wild-type bone marrow cells did not exhibit leukemia at a dose of 33.3 mg/kg body wt and showed a curve with a high probability for the linear regression model with a positive dose intercept, predicting a threshold by the likelihood ratio test. Thus, the failure of wild-type mice to show an increase in incidence of leukemogenesis at low doses of genotoxic carcinogens may be due not to a statistical rarity, but to various p53-related pharmacophysiological functions, possibly including DNA repair and apoptosis that may account for a threshold.
Collapse
Affiliation(s)
- Yoko Hirabayashi
- Cellular and Molecular Toxicology Division, Center for Biological Safety and Research, National Institute of Health Sciences, Tokyo, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Tomisawa M, Suemizu H, Ohnishi Y, Maruyama C, Urano K, Usui T, Yasuhara K, Tamaoki N, Mitsumori K. Mutation analysis of vinyl carbamate or urethane induced lung tumors in rasH2 transgenic mice. Toxicol Lett 2003; 142:111-7. [PMID: 12765245 DOI: 10.1016/s0378-4274(03)00018-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Previous studies showed that significant differences in mutation frequency of the human c-Ha-ras transgene between vinyl carbamate (VC)- and ethyl carbamate (urethane)-induced lung tumors were observed in rasH2 mice. It remains unclear why the point mutation frequency is extremely low in VC-induced lung tumors, although this compound is much more carcinogenic than urethane. In this study, we examined the somatic point mutations of the transgene at the RNA level in VC- and urethane-induced lung tumors of rasH2 mice. We did not find any mutation at codon 12 of the transgene in any of these lung tumors, but codon 61 showed frequent mutations in not only urethane-induced lung tumors (15 out of 16) but also VC-induced lung tumors (11 out of 11) in rasH2 mice. These results suggested that point mutations at codon 61 of the transgene play an important role in the carcinogenesis of VC- and urethane- induced lung tumors in rasH2 mice.
Collapse
Affiliation(s)
- Masashi Tomisawa
- Central Institute for Experimental Animals, 1430 Nogawa, Miyamae-ku, Kawasaki-shi 216-0001, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Takaoka M, Sehata S, Maejima T, Imai T, Torii M, Satoh H, Toyosawa K, Tanakamaru ZY, Adachi T, Hisada S, Ueda M, Ogasawara H, Matsumoto M, Kobayashi K, Mutai M, Usui T. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice. Toxicol Pathol 2003; 31:191-9. [PMID: 12696579 DOI: 10.1080/01926230390183670] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
In order to evaluate a short-term carcinogenicity testing system using CB6F1 -Tg rasH2 (rasH2-Tg) mice carrying a human prototype c-Ha-ras gene, 26-week studies were conducted in 12 different facilities as a part of an International Life Science Institute Health and Environmental Science Institute (ILSI HESI) international collaborative project. In each study N-methyl-N-nitrosourea (MNU) was administered to a separate group of rasH2-Tg mice by single intraperitoneal injection (75 mg/kg) as a positive control. We herein have summarized the mortality, body weight change, and neoplastic and nonneoplastic lesions detected in these positive control groups as representative historical positive control data. Also, we performed an interlaboratory comparison of the response of rasH2-Tg mice to MNU based on the data of 11 positive control groups from these studies. Although the body weight of rasH2-Tg mice showed lower values than that of non-Tgmice during the experimental period, body weight gain in the rasH2-Tg mice was similar to that in non-Tg mice. The mortality of rasH2-Tg mice during the study period was very low, the same as for the non-Tg mice. Incidences of spontaneous alveolar/bronchiolar adenomas and splenic hemangiomas/hemangiosarcomas were also low in the rasH2-Tg mice. Nonneoplastic lesions detected in the rasH2-Tg mice were similar to those in non-Tg mice, excluding the incidence of myopathy. There were interlaboratory differences in mortality and incidence of some lesions in the MNU-treated groups. However, the causes of death were common among the 11 laboratories and almost all the MNU-treated rasH2-Tg mice developed forestomach squamous cell papillomas/carcinomas or malignant lymphomas. This suggests that there is no appreciable difference in the response of the rasH2-Tg mouse to MNU used as a positive control. Therefore, it is concluded that MNU would be an adequate positive control compound in this testing system.
Collapse
Affiliation(s)
- Masaya Takaoka
- Planning and Promotion Department, New Drug Development Division, Sankyo Co, Ltd, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Mitsumori K. POSSIBLE MECHANISM ON ENHANCED CARCINOGENESIS OF GENOTOXIC CARCINOGENS AND UNSOLVED MECHANISMS ON LESSER CARCINOGENIC SUSCEPTIBILITY TO SOME CARCINOGENS IN RASH2 MICE. J Toxicol Sci 2003; 28:371-83. [PMID: 14746341 DOI: 10.2131/jts.28.371] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The rasH2 mice are hemizygous transgenic mice carrying the human prototype c-Ha-ras gene with its own promoter region, and have been used in 6-month short-term carcinogenicity tests for pharmaceutical drugs in accordance with the recommendation of the International Conference on Harmonization of Technical Requirements of Pharmaceuticals for Human Use (ICH). Based on the validation studies, it has been recognized that they are very susceptible to genotoxic carcinogens. To elucidate the mechanism of the enhanced carcinogenesis, spontaneous and chemically induced tumors in rasH2 mice have been subjected to molecular analyses, but the results have thus far been equivocal. This article focuses on the possible molecular mechanism of enhanced carcinogenesis in rasH2 mice, based on the results of a search in the literature. In addition, there are several reports suggesting lesser carcinogenic susceptibility of rasH2 mice to some carcinogens: Malignant lymphomas were induced by treatment with phenolphthalein in heterozygous p53 knockout mice, but not in rasH2 mice, and ethinylestradiol, uterine tumor promoter, resulted in depression of uterine proliferative lesions in rasH2 mice. In this review, the possible mechanisms of why rasH2 mice were less sensitive for these carcinogens are also discussed.
Collapse
Affiliation(s)
- Kunitoshi Mitsumori
- Laboratory of Veterinary Pathology, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu-shi, Tokyo 183-8509
| |
Collapse
|
49
|
Minemura Y, Kashida Y, Watanabe T, Yasuhara K, Takizawa T, Hirose M, Mitsumori K. Modifying Effects of 2,6-Dimethylaniline on Nasal Carcinogenesis in RasH2 Mice Initiated with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone. J Toxicol Pathol 2003. [DOI: 10.1293/tox.16.41] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Yukie Minemura
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology
| | - Yoko Kashida
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology
| | - Takao Watanabe
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology
| | - Kazuo Yasuhara
- Division of Pathology, National Institute of Health Sciences
| | | | - Masao Hirose
- Division of Pathology, National Institute of Health Sciences
| | - Kunitoshi Mitsumori
- Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology
- Division of Pathology, National Institute of Health Sciences
| |
Collapse
|
50
|
Kanno H, Tanakamaru ZY, Ishimura Y, Kandori H, Yamasaki H, Sasaki S. Historical Background Data in CB6F1-Tg-rasH2 Mice and CB6F1-nonTg-rasH2 Mice over a 26-Week Experimental Period. J Toxicol Pathol 2003. [DOI: 10.1293/tox.16.267] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Hiroshi Kanno
- Hikari Branch, Drug Safety Research Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd.,
| | - Zen-yo Tanakamaru
- Hikari Branch, Drug Safety Research Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd.,
| | - Yoshimasa Ishimura
- Hikari Branch, Drug Safety Research Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd.,
| | - Hitoshi Kandori
- Hikari Branch, Drug Safety Research Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd.,
| | - Hideki Yamasaki
- Hikari Branch, Drug Safety Research Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd.,
| | - Satoshi Sasaki
- Hikari Branch, Drug Safety Research Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd.,
| |
Collapse
|